Analyst Price Targets — SION
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 18, 2026 10:45 am | Paul Matteis | Stifel Nicolaus | $55.00 | $40.22 | TheFly | Sionna Therapeutics price target raised to $55 from $44 at Stifel |
| March 2, 2026 4:46 pm | Yatin Suneja | Guggenheim | $50.00 | $34.40 | StreetInsider | Sionna Therapeutics (SION) PT Raised to $50 at Guggenheim following FY25 earnings report |
| January 7, 2026 12:09 pm | Kambiz Yazdi | BTIG | $58.00 | $37.22 | TheFly | Sionna Therapeutics price target raised to $58 from $50 at BTIG |
| January 5, 2026 11:24 am | Chris Raymond | Raymond James | $53.00 | $39.21 | StreetInsider | Sionna Therapeutics (SION) PT Raised to $53 at Raymond James |
| December 1, 2025 10:37 am | — | RBC Capital | $24.00 | $43.57 | TheFly | Sionna downgraded to Underperform from Sector Perform at RBC Capital |
| September 3, 2025 9:27 am | Brian Abrahams | RBC Capital | $22.00 | $26.19 | TheFly | Sionna Therapeutics initiated with a Sector Perform at RBC Capital |
| September 2, 2025 8:44 pm | — | Raymond James | $45.00 | $25.39 | TheFly | Sionna Therapeutics initiated with a Strong Buy at Raymond James |
| March 4, 2025 9:54 am | — | Guggenheim | $45.00 | $14.80 | TheFly | Sionna Therapeutics initiated with a Buy at Guggenheim |
Latest News for SION
Sionna Therapeutics targets cystic fibrosis with a novel NBD1 stabilization mechanism, aiming to enhance CFTR function beyond current standards. SION-719 as an add-on to Trikafta and SION-451 dual combinations both approach pivotal clinical readouts in summer 2026, offering dual strategic paths. Sionna's $289.9M cash runway extends to 2028, supporting critical proof-of-concept milestones without near-term financing…
Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
WALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in the following upcoming investor events:
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th, 2026, at 2:05 p.m. ET.
Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is also on track for topline data in the summer…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SION.
U.S. House Trading
No House trades found for SION.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.